142 related articles for article (PubMed ID: 7774053)
21. Leishmania major: a clone with low virulence for BALB/c mice elicits a Th1 type response and protects against infection with a highly virulent clone.
Li J; Nolan TJ; Farrell JP
Exp Parasitol; 1997 Sep; 87(1):47-57. PubMed ID: 9287957
[TBL] [Abstract][Full Text] [Related]
22. Leishmania major: effect of infectious dose on T cell subset development in BALB/c mice.
Doherty TM; Coffman RL
Exp Parasitol; 1996 Nov; 84(2):124-35. PubMed ID: 8932762
[TBL] [Abstract][Full Text] [Related]
23. IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis.
Scott P
J Immunol; 1991 Nov; 147(9):3149-55. PubMed ID: 1833466
[TBL] [Abstract][Full Text] [Related]
24. Mesenchymal stem cells alter macrophage immune responses to Leishmania major infection in both susceptible and resistance mice.
Dameshghi S; Zavaran-Hosseini A; Soudi S; Shirazi FJ; Nojehdehi S; Hashemi SM
Immunol Lett; 2016 Feb; 170():15-26. PubMed ID: 26703818
[TBL] [Abstract][Full Text] [Related]
25. Leishmania promastigotes evade interleukin 12 (IL-12) induction by macrophages and stimulate a broad range of cytokines from CD4+ T cells during initiation of infection.
Reiner SL; Zheng S; Wang ZE; Stowring L; Locksley RM
J Exp Med; 1994 Feb; 179(2):447-56. PubMed ID: 7905017
[TBL] [Abstract][Full Text] [Related]
26. The Xid defect determines an improved clinical course of murine leishmaniasis in susceptible mice.
Hoerauf A; Solbach W; Lohoff M; Röllinghoff M
Int Immunol; 1994 Aug; 6(8):1117-24. PubMed ID: 7981141
[TBL] [Abstract][Full Text] [Related]
27. Leishmania major-infected murine langerhans cell-like dendritic cells from susceptible mice release IL-12 after infection and vaccinate against experimental cutaneous Leishmaniasis.
von Stebut E; Belkaid Y; Nguyen BV; Cushing M; Sacks DL; Udey MC
Eur J Immunol; 2000 Dec; 30(12):3498-506. PubMed ID: 11093169
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of CD40-induced N-Ras activation reduces leishmania major infection.
Chakraborty S; Srivastava A; Jha MK; Nair A; Pandey SP; Srivastava N; Kumari S; Singh S; Krishnasastry MV; Saha B
J Immunol; 2015 Apr; 194(8):3852-60. PubMed ID: 25786685
[TBL] [Abstract][Full Text] [Related]
29. Tissue expression of inducible nitric oxide synthase is closely associated with resistance to Leishmania major.
Stenger S; Thüring H; Röllinghoff M; Bogdan C
J Exp Med; 1994 Sep; 180(3):783-93. PubMed ID: 7520472
[TBL] [Abstract][Full Text] [Related]
30. Distinct immunological states in murine cutaneous leishmaniasis by immunising with different amounts of antigen: the generation of beneficial, potentially harmful, harmful and potentially extremely harmful states.
Bretscher PA; Ogunremi O; Menon JN
Behring Inst Mitt; 1997 Feb; (98):153-9. PubMed ID: 9382736
[TBL] [Abstract][Full Text] [Related]
31. Ineffective elimination of Leishmania major by inflammatory (MRP14-positive) subtype of monocytic cells.
Steinbrink K; Schönlau F; Rescher U; Henseleit U; Vogel T; Sorg C; Sunderkötter C
Immunobiology; 2000 Nov; 202(5):442-59. PubMed ID: 11205374
[TBL] [Abstract][Full Text] [Related]
32. Early parasite containment is decisive for resistance to Leishmania major infection.
Laskay T; Diefenbach A; Röllinghoff M; Solbach W
Eur J Immunol; 1995 Aug; 25(8):2220-7. PubMed ID: 7664785
[TBL] [Abstract][Full Text] [Related]
33. Susceptibility to Leishmania major in IL-4 transgenic mice is not correlated with the lack of a Th1 immune response.
Erb KJ; Blank C; Moll H
Immunol Cell Biol; 1996 Jun; 74(3):239-44. PubMed ID: 8799723
[TBL] [Abstract][Full Text] [Related]
34. Protective immunity against Leishmania major induced by Leishmania tropica infection of BALB/c mice.
Mahmoudzadeh-Niknam H; Kiaei SS; Iravani D
Exp Parasitol; 2011 Feb; 127(2):448-53. PubMed ID: 21035446
[TBL] [Abstract][Full Text] [Related]
35. Acute cysticercosis favours rapid and more severe lesions caused by Leishmania major and Leishmania mexicana infection, a role for alternatively activated macrophages.
Rodríguez-Sosa M; Rivera-Montoya I; Espinoza A; Romero-Grijalva M; López-Flores R; González J; Terrazas LI
Cell Immunol; 2006 Aug; 242(2):61-71. PubMed ID: 17118349
[TBL] [Abstract][Full Text] [Related]
36. Cellular and humoral immunity to Leishmania major in genetically susceptible mice after in vivo depletion of L3T4+ T cells.
Sadick MD; Heinzel FP; Shigekane VM; Fisher WL; Locksley RM
J Immunol; 1987 Aug; 139(4):1303-9. PubMed ID: 3112230
[TBL] [Abstract][Full Text] [Related]
37. Administration of monoclonal anti-IFN-gamma antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major.
Belosevic M; Finbloom DS; Van Der Meide PH; Slayter MV; Nacy CA
J Immunol; 1989 Jul; 143(1):266-74. PubMed ID: 2499629
[TBL] [Abstract][Full Text] [Related]
38. Effective clearance of intracellular Leishmania major in vivo requires Pten in macrophages.
Kuroda S; Nishio M; Sasaki T; Horie Y; Kawahara K; Sasaki M; Natsui M; Matozaki T; Tezuka H; Ohteki T; Förster I; Mak TW; Nakano T; Suzuki A
Eur J Immunol; 2008 May; 38(5):1331-40. PubMed ID: 18398930
[TBL] [Abstract][Full Text] [Related]
39. TLR9 signaling is essential for the innate NK cell response in murine cutaneous leishmaniasis.
Liese J; Schleicher U; Bogdan C
Eur J Immunol; 2007 Dec; 37(12):3424-34. PubMed ID: 18034422
[TBL] [Abstract][Full Text] [Related]
40. TNF controls the infiltration of dendritic cells into the site of Leishmania major infection.
Ritter U; Lechner A; Scharl K; Kiafard Z; Zwirner J; Körner H
Med Microbiol Immunol; 2008 Mar; 197(1):29-37. PubMed ID: 17661079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
